Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ornidazole effervescent tablet

A technology of ornidazole soaking and ornidazole, which is applied in the field of western medicine preparations, can solve the problems that affect the widespread use, aggravate the burden on the liver and kidney of patients, and kill pathogenic bacteria, etc.

Inactive Publication Date: 2005-05-18
WUHAN FUXING BIOTECH PHARMA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, after capsules and tablets are taken, they are absorbed into the blood through the gastrointestinal tract, and then reach the lesion from the blood. It is also prone to nausea, vomiting, glossitis, anorexia, upper abdominal pain, diarrhea and other gastrointestinal adverse reactions
In addition, oral administration and injection administration are likely to increase the burden on the patient's liver and kidney, which also affects the widespread use of the drug.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ornidazole effervescent tablet
  • Ornidazole effervescent tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] A. Based on 1000 tablets, 250 grams of ornidazole, 100 grams of lactose, 150 grams of tartaric acid, 90 grams of boric acid, 120 grams of sodium bicarbonate, 12 grams of Tween-80, 5 grams of povidone, low-substituted hydroxypropyl Base cellulose 20 grams, magnesium stearate 10 grams, sodium lauryl sulfate 10 grams, above-mentioned raw materials are respectively pulverized, cross 100 mesh sieves, 95% ethanol 100ml, set aside.

[0038] B dissolves Tween-80 and povidone in 95% ethanol to make adhesive, for subsequent use;

[0039] C. Make ornidazole, lactose, and sodium bicarbonate into a soft material with the binder in B above, granulate, and bake at 50-55°C.

[0040] D. Make tartaric acid and boric acid into soft materials with binders, granulate, and bake at 50-55°C.

[0041] F. The above-mentioned granules are sized respectively, mixed, added with low-substituted hydroxypropyl cellulose, sodium lauryl sulfate, and magnesium stearate, mixed evenly, and compressed into...

Embodiment 2

[0053] Vaginal Irritation Test of Ornidazole Effervescent Tablets

[0054] Test materials: drug: ornidazole effervescent tablet, specification: 250mg / tablet. Grind well during the test, and prepare the concentration to be 20mg / ml (referring to the content of ornidazole) with distilled water. The auxiliary material is prepared with distilled water so that the concentration is 40 mg / ml (referring to the auxiliary material content).

[0055] Animals: domestic rabbit, female, 2.0-2.5 kg, provided by Hunan Experimental Rabbit Supply Center.

[0056] experiment method

[0057] 12 rabbits were randomly divided into 3 groups, 4 in each group, (1) blank control group (distilled water), (2) excipient group (adjuvant 60mg / Kg). (3) Ornidazole effervescent tablet group (Ornidazole 30mg / Kg). Gently place the drug (1.5ml / Kg) in the vagina of the rabbit, administer it once a day, for 7 consecutive days, and ensure that the drug is in contact with the mucous membrane for at least 4 hours eve...

Embodiment 3

[0061] Acute Toxicity Test of Ornidazole Effervescent Tablets

[0062] experiment material

[0063] 1. Drug: Ornidazole effervescent tablet, specification: 250mg / tablet. During the test, take ornidazole and grind it evenly, and make it into a concentration of 300 mg / ml (referring to the content of ornidazole) with distilled water. The auxiliary material is prepared with distilled water to a concentration of 300 mg / ml (referring to the auxiliary material content).

[0064] 2. Animals: domestic rabbit, female, 2.0-2.5 kg, provided by Hunan Experimental Rabbit Supply Center.

[0065] experiment method

[0066] 12 rabbits were randomly divided into 3 groups, 4 in each group, (1) blank control group (distilled water), (2) excipient group (adjuvant 450 mg / Kg). (3) Ornidazole effervescent tablet group (Ornidazole 450mg / Kg). Gently place the drug (1.5ml / Kg) in the vagina of the rabbit to ensure that the drug is in contact with the mucous membrane for at least 4 hours. Immediately...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Effervescent Ornidazole tablet contains active component Ornidazole and effervescent tablet supplementary material, each of the effervescent tablet contains Ornidazole in 200-500 mg, and the effervescent tablet supplementary material includes medicinal disintegrating agent and adhesive. The effervescent agent is mixture of NaHCO3 and tartaric acid or tartaric acid and boric acid, and can react with water to generate great amount of CO2 bubble so as to disintegrate in 4-30 min. In the physiological environment inside vagina, the effervescent agent can produce bubbles in the amount of 10-25 ml, expands the medicine contact area and increase local medicine concentration to produce antibacterial and antiphlogistic effect. The present invention may be orally taken and administrated via vagina.

Description

technical field [0001] The invention belongs to the field of western medicine preparations, in particular to a medicine containing an effective dose of ornidazole for treating trichomonas, amoeba, giardia and anaerobic infection in gynecological diseases. Background technique [0002] Trichomonas, amoeba, giardia, anaerobic infection is a common clinical disease. The high incidence and worldwide distribution of amoebiasis and giardiasis make them the main parasitic diseases of humans; trichomoniasis is one of the most common non-viral transmissible diseases. Approximately 2.5-3 million women are affected each year in the United States and 180 million worldwide are exposed to the disease. Since the successful development of metronidazole for the treatment of such diseases, humans have been trying to find ways to find better efficacy and fewer side effects of drugs. Therefore, tinidazole and ornidazole have been developed. [0003] Ornidazole is better than metronidazole in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K9/46A61K31/4168A61P33/02
Inventor 朱志宏
Owner WUHAN FUXING BIOTECH PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com